Gene therapy and gene analysis-related stocks showed mixed movements on the morning of the 7th, varying by individual stock. Tium Bio is leading the gains with a double-digit increase, while CG Invites, Genocheckics (Gencurix), and Rgenomics are also rising sharply. In contrast, some stocks such as Sinteconbio (Syntekabio) and Toolgen are showing clear weakness.

■ Rising Stocks... Tium Bio Soars by Double Digits

As of the morning of the 7th, Tium Bio is trading at 4,970 won, up 13.73% from the previous trading day. It opened at 4,565 won and surged to as high as 5,680 won during the session, with trading volume exceeding 890,000 shares.

CG Invites is trading up 7.09% at 951 won, recording an intraday high of 958 won and a low of 890 won.

Gencurix is also up 4.50% at 1,950 won, having opened at 1,851 won and risen to 1,950 won during the session.

Rgenomics is trading up 3.55% at 29,200 won. During the session, it rose to as high as 30,150 won, breaching the 30,000-won level, with trading volume exceeding 230,000 shares.

In addition, HLB Panacell is up 2.67% at 1,152 won, and VizenCell is up 2.13% at 6,720 won. Genexine is up 1.99%, Geninus up 1.54%, SillaJen up 1.27%, while Kolon Life Science and Amicogen rose 0.67% and 0.69%, respectively. Curecell is up 0.83%. Bioneer and Celemix are each up 0.48%.

■ Falling Stocks... Sinteconbio Pushed Down into the 13% Range

Meanwhile, some related stocks are being pushed down by relatively large margins. Sinteconbio is trading down 13.17% at 1,259 won, with an intraday low of 1,230 won.

Toolgen is down 2.81% at 34,600 won, and CanaPtherapeutics (Kanaph Therapeutics) is down 2.18% at 15,260 won. JS Link is down 2.08%, Genolution down 1.75%, and GoBioLab down 1.03%.

■ Should Be Viewed as 'Individual Stocks' Rather Than a Single Theme

Gene therapy and analysis-related stocks are a sector that is difficult to group into a single business category. Each company possesses different technologies and is at different business stages, ranging from gene therapy and gene editing technology to cell therapy, genome analysis, molecular diagnostics, and precision medicine.

In particular, stock price volatility for new drug development companies can increase depending on clinical trials, technology transfers, and R&D progress. For genome analysis and diagnostics companies, testing demand, product supply, and overseas market expansion can affect their performance.

In today's intraday trading as well, buying is concentrated in some stocks such as Tium Bio and CG Invites, while Sinteconbio and Toolgen are showing weakness. Therefore, rather than treating gene-related stocks as a single theme, it is necessary to examine each company's technology areas, clinical stages, and business performance separately.

[※ This article was written for the purpose of providing information on the domestic stock market and related stocks, and does not recommend buying or selling specific stocks or guarantee investment returns. Stock prices can change rapidly depending on market conditions, and investment decisions and their associated responsibilities rest with the investor. This article was written with AI assistance.]